Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Kymera Therapeutics (NASDAQ: KYMR) reported first dosing in a first-in-human Phase 1 trial of KT-485 (SAR447971), an oral IRAK4 degrader, in healthy adults and hidradenitis suppurativa patients. The Sanofi-led study triggers a $20 million milestone and is part of up to $975 million in potential milestones.
The three-part trial will assess safety, tolerability, pharmacokinetics and exploratory endpoints using SAD, MAD and open-label MAD cohorts.
Kymera Therapeutics (NASDAQ: KYMR) appointed Penny Carlson as Senior Vice President, Development Operations, to oversee global clinical development operations across its oral immunology portfolio. Jeremy Chadwick will retire as Chief Operating Officer, remaining an advisor through year-end.
Carlson brings 20+ years of leadership in clinical program management, study execution and data management.
Kymera Therapeutics (NASDAQ: KYMR) reported new preclinical lupus data for KT-579, an oral IRF5 degrader. KT-579 showed disease-modifying activity in multiple lupus models, with effects described as comparable or superior to approved and clinically active agents, and consistent modulation of Type I IFN, cytokine, and B cell-driven pathways.
The ongoing Phase 1 healthy volunteer trial is assessing safety, tolerability, PK/PD, and IRF5 degradation, with data expected in 2H26 and a patient proof-of-concept trial planned, likely in lupus.
Kymera Therapeutics (NASDAQ: KYMR) will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 8:10 a.m. ET.
A live webcast and archived replay will be available in the Investors “News and Events” section of the company website.
Kymera Therapeutics (NASDAQ: KYMR) reported new Phase 1b data for KT-621, a first-in-class, oral STAT6 degrader, in atopic dermatitis. Presentations at the Society for Investigative Dermatology and American Thoracic Society highlight robust STAT6 degradation in skin and blood, biomarker reductions, and associated clinical efficacy measures.
Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, are ongoing with data expected by mid-2027 and late 2027, respectively, to support potential later Phase 3 development across Type 2 inflammatory diseases.
Kymera Therapeutics (NASDAQ: KYMR) will present at two investor conferences in May 2026 via fireside chats: Bank of America Healthcare Conference in Las Vegas on May 12, 2026 at 9:20 a.m. PT and RBC Capital Markets Global Healthcare Conference in New York on May 19, 2026 at 9:00 a.m. ET.
According to the company, live webcasts and archived replays will be available in the Investors > News and Events section at www.kymeratx.com.
Kymera Therapeutics (NASDAQ: KYMR) presented preclinical data for KT-579, an oral IRF5 degrader, at Digestive Disease Week on May 5, 2026. KT-579 reduced disease activity in a TNBS IBD model, fully inhibited key colon cytokines (TNFα, IL-1β, IL-6), and normalized inflammatory and fibrosis-related transcripts.
The Phase 1 healthy volunteer study is ongoing; the company expects to report human data in the second half of 2026.
Jeito Capital (BIIB) announced the appointments of Elaine Caughey, MBA as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA as Partner, Talent, effective May 5, 2026. Both bring 20+–30+ years of life‑sciences experience across investment funds, pharma and biopharma.
Elaine will support BD, partnerships, acquisitions and U.S. expansion; Sarah will lead senior hiring, board building and talent strategy across the portfolio. The hires complement recent senior additions to strengthen Jeito’s operating and regulatory capabilities.
Kymera Therapeutics (NASDAQ: KYMR) reported Q1 2026 results and pipeline updates. Key highlights: $1.55 billion cash runway into 2029; $34.4M collaboration revenue; Q1 net loss $69.2M. Gilead exercised option on KT-200, triggering a $45M milestone. KT-621 Phase 2b trials (BROADEN2 in AD, BREADTH in asthma) ongoing with data expected mid-2027 and late 2027; FDA granted Fast Track for KT-621 in eosinophilic asthma. KT-579 Phase 1 data expected 2H26. Company to webcast investor call today at 8:30 a.m. ET.
Kymera Therapeutics (NASDAQ: KYMR) will report first quarter 2026 financial results on April 30, 2026. The company will host a video conference call and webcast at 8:30 a.m. ET that day. Registration and a replay will be available via the Investors section at www.kymeratx.com.